5-HT2R NEUROBIOLOGY IN ANIMAL MODELS OF ADDICTION
成瘾动物模型中的 5-HT2R 神经生物学
基本信息
- 批准号:8467831
- 负责人:
- 金额:$ 16.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至 2013-12-31
- 项目状态:已结题
- 来源:
- 关键词:AbstinenceAgonistAnimal ModelBehaviorBehavior ControlBehavioralBiological AssayBiological AvailabilityBiological MarkersBlood PlateletsBrainClinicalClinical TrialsClinical assessmentsCocaineCocaine DependenceCuesDataDoseDrug DesignEffectivenessEquilibriumEtiologyExhibitsFloorFutureGoalsHomoHumanImpulsivityIndividualInterventionKnowledgeLaboratory StudyLigandsLinkMethodologyModelingMolecularNeurobiologyOutcomePatternPharmaceutical PreparationsPsychological reinforcementPsychostimulant dependenceRattusRelapseResearchRodentRodent ModelRoleScheduleSelf AdministrationSerotoninSerotonin AgentsShapesStagingSystemTestingTimeTranslationsTreatment Effectivenessabstractingaddictionbasebehavior measurementcue reactivitydesignendophenotypeexperiencefunctional statusin vivoinsightmeetingsneurochemistryneuroimagingnovelpre-clinicalresearch studyresponsetreatment effecttreatment response
项目摘要
common shared clinical question of the Translational Center for Serotonin and Stimulant Addiction
(TCSSA) is the role of 5-HT neurobiology in impulsivity and cue reactivity endophenotypes which associate
with cocaine addiction. Project 2 will employ and refine behavioral measures of impulsivity and cue reactivity
in rats, mechanistically link the status of 5-HT^R and/or 5-HT2cR expression and function to specific
behavioral profiles, and test the hypothesis that treatment with M100907 (selective S-HT^R antagonist),
WAY 470 (selective 5-HT2cR agonist) or their combination will normalize behavioral and molecular patterns
of expression. We will initially identify the endophenotype for impulsivity based upon the degree of response
inhibition in the differential reinforcement of low rates schedule (DRL-20) task and for cue reactivity based
upon lever responses reinforced by drug-associated cues during forced abstinence from a well-defined
cocaine self-administration paradigm. We will also investigate how basal levels of impulsivity interact with the
progression of drug-taking and drug-seeking. In concert with Project 3, we propose that gains in treatment
effectiveness will be possible with the selective homo- and/or heterodimeric 5-HT2R ligands. Promising
compounds will be evaluated for in vivo bioavailability in a stairstep approach utilizing simple rodent assays
that will also serve as dose-ranging studies for the more intensive assessment of their effectiveness in
models of impulsivity and cue reactivity. Project 2 will be driven and adapted directly from the clinical
neurobiology insight (Project 1) and take a molecular-level view to elaborating the role of 5-HT in targeted
endophenotypes (Project 3, Core B). Careful analyses of the status of 5-HT^R and 5-HT2CR expression and
function and the effects of treatment with extant and novel selective 5-HT^R and 5-HT2cR ligands or their
combination, in rodent models will shape the rationale for future hypothesis-driven neurobiological studies in
humans (Project 1) and clinical assessments of new selectively-targeted serotonergic drugs (Project 3).
Lav Abstract. No effective, accessible medication for the treatment of stimulant addiction is currently
available. We will establish the ability of existing and newly designed drugs to suppress relapse in rodent
assays which model human drug-taking.
5-羟色胺和兴奋剂成瘾转化中心的共同临床问题
(TCSSA)是5-HT神经生物学在冲动性和线索反应性内表型中的作用,
可卡因成瘾项目2将采用和完善冲动和线索反应的行为措施
在大鼠中,将5-HT 2 R和/或5-HT 2cR表达和功能的状态与特异性
行为特征,并检验用M100907(选择性S-HT^R拮抗剂)治疗,
WAY 470(选择性5-HT 2cR激动剂)或其组合将使行为和分子模式正常化
的表达。我们将根据反应程度初步确定冲动的内在表型
抑制在差异强化低利率时间表(DRL-20)的任务和线索反应性为基础的
在强迫戒除明确定义的药物期间,药物相关线索强化了杠杆反应
可卡因自我给药模式。我们还将研究冲动的基础水平如何与
吸毒和寻求毒品的进展。与项目3一致,我们建议,
使用选择性同二聚体和/或异二聚体5-HT 2 R配体可能有效。有前途
化合物的体内生物利用度将利用简单的啮齿动物试验以阶梯方法进行评价
这也将作为剂量范围研究,以更深入地评估其在以下方面的有效性:
冲动和线索反应的模型。项目2将直接从临床
神经生物学洞察力(项目1),并采取分子水平的观点来阐述5-HT在靶向
内表型(项目3,核心B)。仔细分析5-HT 2 R和5-HT 2CR表达的状态,
功能和用现存的和新的选择性5-HT 2cR和5-HT 2cR配体或其
组合,在啮齿动物模型中将形成未来假设驱动的神经生物学研究的基本原理,
人类(项目1)和新型选择性靶向血清素能药物的临床评估(项目3)。
拉夫摘要。目前还没有有效的、可获得的治疗兴奋剂成瘾的药物。
available.我们将确定现有的和新设计的药物抑制啮齿动物复发的能力。
模拟人类吸毒的试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kathryn A. Cunningham其他文献
Proteomics analyses: Peroxisome proliferator-activated receptor gamma agonist for chronic cocaine administration in rodents
- DOI:
10.1016/j.drugalcdep.2015.07.590 - 发表时间:
2015-11-01 - 期刊:
- 影响因子:
- 作者:
Nilesh S. Tannu;Joy Schmitz;Scott D. Lane;C. Green;Kathryn A. Cunningham;Robert Suchting;Juan Herrera;P.A. Narayana - 通讯作者:
P.A. Narayana
Changes in brain white matter integrity after Ppar-gamma agonist treatment for cocaine use disorder
- DOI:
10.1016/j.drugalcdep.2016.08.316 - 发表时间:
2017-02-01 - 期刊:
- 影响因子:
- 作者:
Scott D. Lane;Khader M. Hasan;Benson Mwangi;P.A. Narayana;Jessica Vincent;F. Gerard Moeller;Joel Steinberg;Kelly Dineley;Kathryn A. Cunningham;Joy Schmitz - 通讯作者:
Joy Schmitz
Novel bivalent serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor ligands demonstrate distinct activities <em>in vitro and in vivo</em>
- DOI:
10.1016/j.drugalcdep.2015.07.1164 - 发表时间:
2015-11-01 - 期刊:
- 影响因子:
- 作者:
Rachel M. Hartley;Scott Gilbertson;Ying-Chu Chen;Noelle C. Anastasio;Robert G. Fox;Sonja J. Stutz;Cheryl Watson;Kathryn A. Cunningham - 通讯作者:
Kathryn A. Cunningham
Effective connectivity of attentional bias in cocaine dependence
- DOI:
10.1016/j.drugalcdep.2016.08.405 - 发表时间:
2017-02-01 - 期刊:
- 影响因子:
- 作者:
F. Gerard Moeller;Liangsuo Ma;Joel Steinberg;James Bjork;Scott D. Lane;P.A. Narayana;Thomas Kosten;Antoine Bechara;Joy Schmitz;Amanda E. Price;Kathryn A. Cunningham - 通讯作者:
Kathryn A. Cunningham
The SoTL Scaffold: Supporting Evidence-Based Teaching Practice in Educational Development
SoTL 支架:支持教育发展中的循证教学实践
- DOI:
- 发表时间:
2019 - 期刊:
- 影响因子:0
- 作者:
Laura Cruz;Kathryn A. Cunningham;Brian Smentkowski;H. Steiner - 通讯作者:
H. Steiner
Kathryn A. Cunningham的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kathryn A. Cunningham', 18)}}的其他基金
Novel Addiction Neurocircuits in Cocaine Taking
可卡因吸食中的新型成瘾神经回路
- 批准号:
10595681 - 财政年份:2022
- 资助金额:
$ 16.61万 - 项目类别:
Mechanisms of prenatal opioid exposure on brain and behavior
产前阿片类药物暴露对大脑和行为的机制
- 批准号:
10375927 - 财政年份:2022
- 资助金额:
$ 16.61万 - 项目类别:
Novel Addiction Neurocircuits in Cocaine Taking
可卡因吸食中的新型成瘾神经回路
- 批准号:
10375964 - 财政年份:2022
- 资助金额:
$ 16.61万 - 项目类别:
Mechanisms of prenatal opioid exposure on brain and behavior
产前阿片类药物暴露对大脑和行为的机制
- 批准号:
10657323 - 财政年份:2022
- 资助金额:
$ 16.61万 - 项目类别:
NOP Receptor Antagonist for OUD Pharmacotherapy
用于 OUD 药物治疗的 NOP 受体拮抗剂
- 批准号:
10085851 - 财政年份:2020
- 资助金额:
$ 16.61万 - 项目类别:
Targeting the Ghrelin System for Novel Opioid Use Disorder Therapeutics
针对新型阿片类药物使用障碍治疗的 Ghrelin 系统
- 批准号:
9905262 - 财政年份:2019
- 资助金额:
$ 16.61万 - 项目类别:
Targeting the Ghrelin System for Novel Opioid Use Disorder Therapeutics
针对新型阿片类药物使用障碍治疗的 Ghrelin 系统
- 批准号:
10168769 - 财政年份:2019
- 资助金额:
$ 16.61万 - 项目类别:
Neural and Pharmacological Mechanisms of Abused Drugs
滥用药物的神经和药理学机制
- 批准号:
9404132 - 财政年份:2016
- 资助金额:
$ 16.61万 - 项目类别:
5-HT2 Receptor Allosterism in Cocaine Use Disorder
可卡因使用障碍中的 5-HT2 受体变构
- 批准号:
10445173 - 财政年份:2015
- 资助金额:
$ 16.61万 - 项目类别:
5‐HT2CR ALLOSTERIC MODULATORS AS NOVEL PHARMACOTHERAPY IN COCAINE USE DISORDER
5-HT2CR 变构调节剂作为可卡因使用障碍的新型药物治疗
- 批准号:
9271312 - 财政年份:2015
- 资助金额:
$ 16.61万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 16.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 16.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 16.61万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 16.61万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 16.61万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 16.61万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 16.61万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 16.61万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 16.61万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 16.61万 - 项目类别: